Coleman Mark 4

What Happened

• Mark Coleman, a director of Axsome Therapeutics (AXSM), sold a total of 17,537 shares across three open‑market transactions between May 29 and June 2, 2026, for aggregate proceeds of about $4,019,470 (~$4.02M).
  • 2026-05-29: 6,000 shares at $233.46 — $1,400,760
  • 2026-06-01: 6,000 shares at $230.30 — $1,381,800
  • 2026-06-02: 5,537 shares at $223.39 — $1,236,910
• These were sales (not purchases); sales are often routine insider liquidity events and do not by themselves indicate company performance.

Key Details

• Transaction dates/prices: 5/29/2026 ($233.46), 6/1/2026 ($230.30), 6/2/2026 ($223.39).
• Total shares sold: 17,537; total proceeds: ~$4.02 million.
• Shares owned after transaction: Not specified in the provided filing data.
• Notable footnotes from the filing: the shares sold represent underlying shares from previously exercised stock options; some transactions were executed pursuant to a pre‑approved 10b5‑1 trading plan; reported prices are weighted averages across series of open‑market trades (ranges provided in the filing). The filing also notes indirect ownership of some shares via an entity controlled by the reporting person.
• Filing date: June 2, 2026. The report appears to have been filed promptly (within the normal 2 business‑day Form 4 window) covering the sales through June 2.

Context

• The filing indicates these sales involved shares that originated from previously exercised stock options (i.e., the insider sold underlying shares rather than newly granted awards). Where a 10b5‑1 plan is used, trades are pre‑planned and generally considered routine.
• For retail investors: purchases by insiders often attract more attention as potential bullish signals; sales can reflect personal liquidity decisions and should be interpreted alongside other information (timing, volume, and company fundamentals).